Dr Jennifer Taylor-Cousar (National Jewish Health, Denver, CO, USA) explores what we have learnt so far about how COVID-19 is effecting patients with cystic fibrosis.
Questions
1. What is the risk to cystic fibrosis patients from COVID-19 and what have we learned from reported cases so far? (0:07)
2. It seems that, to date, cystic fibrosis patients have only experienced mild symptoms. What do think is the reason for this? (1:08)
3. How are healthcare providers managing the routine care of patients with cystic fibrosis during the pandemic? (2:58)
4. If a cystic fibrosis patient has COVID-19, how does this impact on their day to day treatment? (3:36)
5. How can cystic fibrosis patients with COVID-19 avoid infecting other people while using non-invasive ventilation in a hospital setting? (4:26)
Speaker disclosure: Dr Taylor-Cousar has acted as a PI on studies for Vertex and Proteostasis; a consultant/advisor for Proteostasis, Santhera, 4DMT and Vertex; and a speaker for Vertex. She has also received grant funding from the CF Foundation; serves on the CF Foundation’s Clinical Research Executive Committee and Clinical Research Advisory Board; and is chair-elect of the ATS Clinical Problems Assembly Programming Committee.
touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Commissioned, edited and supported by Touch Medical Media
Filmed on Thursday 9 April 2020.
